Updated:
Quotient Sciences
Quotient Sciences is a drug development & manufacturing accelerator. As a pharmaceutical CRDMO we support customers from candidate selection to commercial...
Quotient Sciences
Quotient Sciences is a drug development & manufacturing accelerator. As a pharmaceutical CRDMO we support customers from candidate selection to commercial launch. Pharmaceutical CRDMO, Small Molecule Drug Development, Phase 1 Clinical Trials, Drug Manufacturing, Clinical Research
General information
Firm type
other
Year founded
1990
Location
Region
Europe
Country
United Kingdom
City
Nottingham
Corporate office
Nottingham, United Kingdom
Additional offices
Philadelphia, United States · Miami, United States · Reading, United Kingdom · Alnwick, United Kingdom
Sector focus
Frequently asked questions
What is Quotient Sciences' core business model?
Quotient Sciences operates as a contract research and manufacturing organization (CRDMO) that provides integrated drug development services for small molecule and synthetic peptide therapeutics. Its model combines formulation, clinical testing, and manufacturing under one provider, which the company calls Translational Pharmaceutics. This integration is designed to reduce development timelines by eliminating handoffs between separate vendors.
Does Quotient Sciences manage outside investor capital?
No. Quotient Sciences is an operating company, not an investment vehicle. It generates revenue by providing contract services to pharmaceutical and biotechnology clients. The company does not publish AUM or deployment figures.
Where does Quotient Sciences operate?
The company has major facilities in the United States (Philadelphia, Pennsylvania and Miami, Florida) and the United Kingdom (Nottingham, Reading, and Alnwick). These sites support drug product manufacturing, clinical trial execution, and analytical services. The headquarters is in Nottingham, UK.
What types of drug molecules does Quotient Sciences work with?
Quotient Sciences specializes in small molecule and synthetic peptide drug development. It provides services from candidate selection through commercial launch, including formulation development, Phase I clinical trials, and commercial manufacturing.
Has Quotient Sciences won any industry awards?
Yes. The company has been a multiyear winner of CRO Leadership Awards, most recently in 2024, and won CDMO Leadership Awards in 2023. In 2024, it also received a Fierce CRO Award for Innovative Solutions in Drug Development for its Translational Pharmaceutics platform.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: